Morgan Stanley Says Too Soon to Turn Bullish on Stocks

image

(Bloomberg) — Even as the S&P 500 on Friday narrowly avoided plunging into a bear market, Morgan Stanley strategists say it’s too early to turn optimistic on stocks.

“Equity clients are bearish, a necessary condition for a sustainable low, but an insufficient one,” strategists led by Michael Wilson wrote in a note on Monday. “Given the risks to growth are just emerging, it’s too early to get bullish.”

US stocks have been roiled in the past two months, with the S&P 500 on Friday posting its longest weekly losing streak since 2001 and flirting with a bear market, on concerns that the Federal Reserve’s tightening will push the economy into a recession. A Bank of America Corp. fund manager survey last week showed recession fears trumped the tail risks from inflation and the war in Ukraine, with investors turning the most underweight on equities in two years.

Morgan Stanley’s Wilson, who continues to be among Wall Street’s most prominent bears and who correctly predicted the latest market selloff, said the biggest areas of risk include the consumers’ ability and willingness to spend, margin pressure, excess inventory and a cyclical downturn for tech spending.

Wilson said 3,400 points for the S&P 500 — 13% lower from the current level — more accurately reflects the risks to earnings growth, and expects to see this level by the end of the second-quarter earnings season.

“Until then, vicious bear market rallies should be used to lighten up on the areas most vulnerable to the oncoming earnings reset,” he said.

The strategist retains underweight positioning in cyclical technology and consumer discretionary stocks, and is neutral on internet and software shares.

At the same time, not everyone is as pessimistic. Goldman Sachs Group Inc.’s David J. Kostin expects the S&P 500 to end this year 10% higher thanks to a forecast 8% earnings-per-share growth.

©2022 Bloomberg L.P.

 
Trending Ideas

Featured Stocks On The Move

Daily Rundown

Top 3 Stocks in Leading Sectors
  • 3 Software Stocks To Buy Now

    International Business Machines Corporation (IBM) International Business Machines Corporation (IBM) is a global leader in cloud computing, AI, and enterprise software. The company provides IT infrastructure, cybersecurity, and quantum computing... Read More

  • 3 Food Stocks To Buy Now

    The Campbell’s Company (CPB) The Campbell’s Company is a leading producer of packaged foods and beverages, known for its soups, sauces, and snacks. With brands like Campbell’s, Pepperidge Farm, and... Read More

  • 3 Utility Stocks To Buy Now

    IDACORP, Inc. (IDA) IDACORP, Inc. is a utility holding company that provides electricity through its subsidiary, Idaho Power. The company focuses on renewable energy initiatives, grid modernization, and sustainable power... Read More

  • 3 Biotechnology Stocks To Buy Now

    Xeris Biopharma Holdings, Inc. (XERS) Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative injectable drug formulations. Its proprietary technology enhances drug stability and... Read More

  • 3 Consumer Service Stocks To Buy Now

    TripAdvisor, Inc. (TRIP) TripAdvisor, Inc. operates the world’s largest travel guidance platform, offering user-generated reviews, price comparisons, and booking services for hotels, attractions, and restaurants worldwide. Chart Wynn Resorts, Limited... Read More

  • 3 Software Stocks To Buy Now

    Udemy, Inc. (UDMY) Udemy, Inc. is an online learning platform offering a vast catalog of courses across various fields. The company connects learners with expert instructors, providing affordable and accessible... Read More

  • 3 Energy Stocks To Buy Now

    Ranger Energy Services, Inc. (RNGR) Ranger Energy Services, Inc. provides well services and support for oil and gas production. The company specializes in high-spec rig solutions, completion services, and workover... Read More

  • 3 Pharmaceutical Stocks To Buy Now

    ACADIA Pharmaceuticals Inc. (ACAD) ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s lead product, NUPLAZID, is used to treat Parkinson’s... Read More